GTC
SWTX

Ghost Tree Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Ghost Tree Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,578
Closed -$723K – 79
2023
Q2 		$723K Hold
27,578
– – 0.24% 47
2023
Q1 		$710K Buy
+27,578
New +$806K 0.21% 53

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's SWTX Position: Q3 2023 in Review

Ghost Tree Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2023, closing a stake of 27,578 shares — an estimated $723K sold.

Ghost Tree Capital first reported a position in SWTX in Q1 2023 and held it in 2 quarters. The position peaked at $723K in Q2 2023. 147 funds tracked by Wall St. Rank hold SWTX as of Q3 2023.

  • Ghost Tree Capital reported no remaining SpringWorks Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 27,578 SpringWorks Therapeutics shares in Q3 2023, an estimated $723K.
  • Ghost Tree Capital first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 2 quarters.
  • Ghost Tree Capital's SpringWorks Therapeutics position peaked at $723K in Q2 2023.
  • 147 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.